<b>Background</b>: Finerenone and sodium-glucose cotransporter-2 inhibitors provide cardiovascular and renal benefits in patients with chronic kidney disease (CKD) and heart failure (HF), but real-world comparative evidence is limited. Here, SLC5A2 is linked to chronic kidney disease.